Insulet (PODD) Cash from Operations Growth (1y) (2011 - 2026)
Insulet (PODD) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 122.43% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 78.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.37% |
| Dec 31, 2025 | 24.27% |
| Sep 30, 2025 | 16.07% |
| Jun 30, 2025 | 126.38% |
| Mar 31, 2025 | -27.17% |
| Dec 31, 2024 | 226.33% |
| Sep 30, 2024 | 93.39% |
| Jun 30, 2024 | 97.27% |
| Mar 31, 2024 | 17,420.00% |
| Dec 31, 2023 | -10.85% |
| Sep 30, 2023 | -1.23% |
| Jun 30, 2023 | 73.91% |
| Mar 31, 2023 | 103.65% |
| Dec 31, 2022 | 298.82% |
| Sep 30, 2022 | 319.77% |
| Jun 30, 2022 | 38.25% |
| Mar 31, 2022 | 60.97% |
| Dec 31, 2021 | -250.00% |
| Sep 30, 2021 | -158.37% |
| Jun 30, 2021 | -30.68% |